8-K: Ultragenyx Reports Strong Q3 Revenue Growth and Pipeline Advancements

Ultragenyx announced a 42% year-over-year revenue increase in the third quarter of 2024, driven by strong sales of Crysvita and Dojolvi, and provided updates on its clinical programs.

Summary

• Ultragenyx reported total revenue of $139 million for the third quarter of 2024, a 42% increase compared to the same period in 2023.
• Crysvita revenue reached $98 million, a 31% increase year-over-year, with product sales in Latin America and Turkey growing by 85%.
• Dojolvi revenue was $21 million, a 29% increase compared to the third quarter of 2023.
• Evkeeza revenue was $11 million, showing continued growth outside the United States.
• The company reaffirmed its 2024 total revenue guidance of $530 million to $550 million.
• Operating expenses for the quarter were $271 million, including $42 million in non-cash stock-based compensation.
• Net loss for the quarter was $134 million, or $1.40 per share, compared to a net loss of $160 million, or $2.23 per share, in the same quarter of 2023.
• Net cash used in operations was $67 million for the quarter and $335 million for the nine months ended September 30, 2024.
• Cash, cash equivalents, and marketable debt securities totaled $825 million as of September 30, 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, clinical advancements, and a solid cash position. The Breakthrough Therapy Designation and positive clinical trial results are particularly encouraging. However, the net loss and operating expenses temper the overall sentiment slightly.

Positives

• The company experienced substantial year-over-year revenue growth from its commercial portfolio.
• Crysvita sales showed strong growth, particularly in Latin America and Turkey.
• Dojolvi sales also demonstrated significant growth.
• Evkeeza is gaining traction in international markets.
• The company is on track to meet its 2024 revenue guidance.
• Setrusumab received Breakthrough Therapy Designation, which could expedite its development.
• DTX401 showed promising results in reducing cornstarch intake in GSDIa patients.
• The company has aligned with the PMDA for a conditional filing for Dojolvi in Japan.
• The company has successfully completed a pre-BLA meeting with the FDA for UX111.
• The company has a strong cash position of $825 million.

Negatives

• The company reported a net loss of $134 million for the third quarter of 2024.
• Operating expenses remain high at $271 million for the quarter.
• Net cash used in operations was $67 million for the quarter and $335 million for the nine months ended September 30, 2024.

Risks

• The company faces risks associated with clinical drug development and regulatory approvals.
• There are risks related to potential side effects of product candidates.
• The company relies on third-party partners for certain activities.
• There are risks related to product liability lawsuits.
• The company is dependent on Kyowa Kirin for the commercial supply of Crysvita.
• The company faces competition from other therapies and products.
• There are risks related to manufacturing and market opportunities.

Future Outlook

The company expects total revenue to be in the range of $530 million to $550 million for the full year 2024, with Crysvita revenue towards the upper end of the $375 million to $400 million range and Dojolvi revenue in the range of $75 million to $80 million. Net cash used in operations is expected to be around $400 million for the year.

Management Comments

• Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx, stated that the company continues to see substantial year-over-year revenue growth from its commercial portfolio as they expand geographic access to their medicines.
• Emil D. Kakkis also mentioned that this growth could accelerate with up to three near-term BLA submissions and approvals.
• Emil D. Kakkis highlighted the important update from the Phase 3 study in GSDIa with substantially larger reductions in cornstarch intake in crossover patients treated with DTX401.

Industry Context

This announcement reflects the ongoing growth and development in the rare disease therapeutics sector. Ultragenyx's focus on novel therapies for rare genetic diseases aligns with the industry's trend towards addressing unmet medical needs in this area. The company's progress in clinical trials and regulatory submissions is indicative of the competitive landscape in the biopharmaceutical industry.

Comparison to Industry Standards

• Ultragenyx's 42% revenue growth in Q3 2024 is strong compared to many other biotech companies, especially those focused on rare diseases. For example, companies like BioMarin Pharmaceutical Inc. and Sarepta Therapeutics, Inc. have also shown growth, but the specific rates vary based on their product portfolios and market dynamics.
• The Breakthrough Therapy Designation for setrusumab is a positive sign, as it can expedite the development process, similar to how other companies have benefited from this designation for their therapies. For example, Vertex Pharmaceuticals has seen accelerated development for some of their cystic fibrosis treatments.
• The 62% mean reduction in cornstarch intake in GSDIa patients treated with DTX401 is a significant result, potentially exceeding the efficacy of existing treatments. This is comparable to other gene therapy trials that have shown substantial improvements in patient outcomes, such as those seen in some of the early gene therapy trials for spinal muscular atrophy (SMA).
• The company's cash position of $825 million is robust, providing a solid foundation for continued research and development. This is comparable to other well-funded biotech companies in the rare disease space, such as Alnylam Pharmaceuticals, Inc., which also maintains a strong cash balance to support their pipeline.

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue growth and clinical advancements.
• Employees may be encouraged by the company's progress and future prospects.
• Patients with rare diseases may benefit from the development of new therapies.
• Suppliers and partners may see increased business opportunities.
• Creditors may view the company's financial position favorably.

Next Steps

• The company plans to file a J-NDA for Dojolvi in Japan in mid-2025.
• The company expects to file a BLA for UX111 around the end of 2024.
• The company plans to initiate the pivotal Phase 3 Aspire study for GTX-102 by the end of 2024.
• The company plans to initiate the Aurora study for GTX-102 in 2025.
• The company plans to submit a BLA for DTX401 in mid-2025.
• The company expects to enroll an additional cohort in Stage 1 of the UX701 study.
• The company expects to complete enrollment in the Phase 3 study for DTX301 in the next few months.

Key Dates

Keywords

Ultragenyx, Rare Diseases, Biopharmaceutical, Crysvita, Dojolvi, Evkeeza, Setrusumab, DTX401, Gene Therapy, Financial Results, Clinical Trials, FDA, Breakthrough Therapy Designation, GSDIa, Osteogenesis Imperfecta